Deciphering the Causal Role of sPLA2s and Lp-PLA2 in Coronary Heart Disease.
Oxford, United Kingdom. In Arterioscler Thromb Vasc Biol, Nov 2015
Over the last 10 to 15 years, animal and human observational studies have identified elevated levels of both proinflammatory secretory phospholipase A2-IIA and lipoprotein-associated phospholipase A2 as potential risk factors for coronary heart disease.
Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications.
Padova, Italy. In World J Cardiol, Nov 2015
Promising results along this line were provided by studies investigating the lipoprotein-associated phospholipase A2 (Lp-PLA2), a member of phospholipase A2 proteins family that plays a key role in the metabolism of pro-inflammatory phospholipids, as oxidized low-density lipoproteins, and in the generation of pro-atherogenic metabolites, including lysophosphatidylcholine and oxidized free fatty acids.
[Lp-PLA2, a biomarker of vascular inflammation and vulnerability of atherosclerosis plaques].
Paris, France. In Ann Pharm Fr, Nov 2015
Among the emerging biomarkers of atherogenesis, the lipoprotein-associated phospholipase A2 (Lp-PLA2), formerly known as PAF-acetylhydrolase (McIntyre et al., 2009), hydrolyses the oxidized short chain phospholipids of low-density lipoproteins (LDL), thereby releasing pro-inflammatory mediators (lysophospholipids and oxidized fatty acids).